Chemical Compound Review:
Draganon 1-(4-methoxyphenyl) carbonylpyrrolidin-2-one
Synonyms:
Memodrin, Ampamet, Sarpul, aniracetam, Reset, ...
- Effects of aniracetam on bladder overactivity in rats with cerebral infarction. Nakada, Y., Yokoyama, O., Komatsu, K., Kodama, K., Yotsuyanagi, S., Niikura, S., Nagasaka, Y., Namiki, M. J. Pharmacol. Exp. Ther. (2000)
- Delayed, post-injury treatment with aniracetam improves cognitive performance after traumatic brain injury in rats. Baranova, A.I., Whiting, M.D., Hamm, R.J. J. Neurotrauma (2006)
- Nicergoline stimulates protein kinase C mediated alpha-secretase processing of the amyloid precursor protein in cultured human neuroblastoma SH-SY5Y cells. Cedazo-Minguez, A., Bonecchi, L., Winblad, B., Post, C., Wong, E.H., Cowburn, R.F., Benatti, L. Neurochem. Int. (1999)
- Erk1/2 and Akt kinases are involved in the protective effect of aniracetam in astrocytes subjected to simulated ischemia in vitro. Gabryel, B., Pudelko, A., Malecki, A. Eur. J. Pharmacol. (2004)
- Aniracetam reverses the anticonvulsant action of NBQX and GYKI 52466 in DBA/2 mice. Chapman, A.G., al-Zubaidy, Z., Meldrum, B.S. Eur. J. Pharmacol. (1993)
- Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. Zhao, X., Kuryatov, A., Lindstrom, J.M., Yeh, J.Z., Narahashi, T. Mol. Pharmacol. (2001)
- Aniracetam tested in chronic psychosyndrome after long-term exposure to organic solvents. A randomized, double-blind, placebo-controlled cross-over study with neuropsychological tests. Somnier, F.E., Ostergaard, M.S., Boysen, G., Bruhn, P., Mikkelsen, B.O. Psychopharmacology (Berl.) (1990)
- Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions. Nabeshima, T., Noda, Y., Tohyama, K., Itoh, J., Kameyama, T. Eur. J. Pharmacol. (1990)
- Impulsivity and AMPA receptors: aniracetam ameliorates impulsive behavior induced by a blockade of AMPA receptors in rats. Nakamura, K., Kurasawa, M., Shirane, M. Brain Res. (2000)
- Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study. Senin, U., Abate, G., Fieschi, C., Gori, G., Guala, A., Marini, G., Villardita, C., Parnetti, L. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. (1991)
- Modulation of the time course of fast EPSCs and glutamate channel kinetics by aniracetam. Tang, C.M., Shi, Q.Y., Katchman, A., Lynch, G. Science (1991)
- Modulation of excitatory synaptic transmission by drugs that reduce desensitization at AMPA/kainate receptors. Vyklicky, L., Patneau, D.K., Mayer, M.L. Neuron (1991)
- 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys. Thompson, D.M., Guidotti, A., DiBella, M., Costa, E. Proc. Natl. Acad. Sci. U.S.A. (1995)
- AMPA receptor flip/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate. Partin, K.M., Fleck, M.W., Mayer, M.L. J. Neurosci. (1996)
- N-methyl-D-aspartate neurotoxicity in hippocampal slices: protection by aniracetam. Pizzi, M., Consolandi, O., Memo, M., Spano, P. Eur. J. Pharmacol. (1995)
- Nootropic drugs and brain cholinergic mechanisms. Pepeu, G., Spignoli, G. Prog. Neuropsychopharmacol. Biol. Psychiatry (1989)
- Effects of D-cycloserine and aniracetam on spatial learning in rats with entorhinal cortex lesions. Zajaczkowski, W., Danysz, W. Pharmacol. Biochem. Behav. (1997)
- WEB 1881 FU ameliorates impairment of working memory induced by scopolamine and cerebral ischemia in the three-panel runway task. Ohno, M., Yamamoto, T., Kitajima, I., Ueki, S. Jpn. J. Pharmacol. (1990)
- Treatment of insomnia by concomitant therapy with Zopiclone and Aniracetam in patients with cerebral infarction, cerebroatrophy, Alzheimer's disease and Parkinson's disease. Katsunuma, H., Shimizu, T., Ogawa, K., Kubo, H., Ishida, H., Yoshihama, A. Psychiatry and clinical neurosciences. (1998)
- Selective effects of aniracetam across receptor types and forms of synaptic facilitation in hippocampus. Xiao, P., Staubli, U., Kessler, M., Lynch, G. Hippocampus. (1991)
- Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. Ito, I., Tanabe, S., Kohda, A., Sugiyama, H. J. Physiol. (Lond.) (1990)
- Facilitation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor transmission in the suprachiasmatic nucleus by aniracetam enhances photic responses of the biological clock in rodents. Moriya, T., Ikeda, M., Teshima, K., Hara, R., Kuriyama, K., Yoshioka, T., Allen, C.N., Shibata, S. J. Neurochem. (2003)
- Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures. Copani, A., Genazzani, A.A., Aleppo, G., Casabona, G., Canonico, P.L., Scapagnini, U., Nicoletti, F. J. Neurochem. (1992)
- Receptor changes and LTP: an analysis using aniracetam, a drug that reversibly modifies glutamate (AMPA) receptors. Staubli, U., Ambros-Ingerson, J., Lynch, G. Hippocampus. (1992)
- Antidepressant-like effects of aniracetam in aged rats and its mode of action. Nakamura, K., Tanaka, Y. Psychopharmacology (Berl.) (2001)
- Group II metabotropic glutamate receptors are a common target of N-anisoyl-GABA and 1S,3R-ACPD in enhancing ACh release in the prefrontal cortex of freely moving SHRSP. Shirane, M., Nakamura, K. Neuropharmacology (2000)
- The "kynurenate test", a biochemical assay for putative cognition enhancers. Pittaluga, A., Vaccari, D., Raiteri, M. J. Pharmacol. Exp. Ther. (1997)
- Enhancement of contextual fear-conditioning by putative (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor modulators and N-methyl-D-aspartate (NMDA) receptor antagonists in DBA/2J mice. Lu, Y., Wehner, J.M. Brain Res. (1997)
- Site-specific activation of dopamine and serotonin transmission by aniracetam in the mesocorticolimbic pathway of rats. Nakamura, K., Shirane, M., Koshikawa, N. Brain Res. (2001)
- AMPA protects cultured neurons against glutamate excitotoxicity through a phosphatidylinositol 3-kinase-dependent activation in extracellular signal-regulated kinase to upregulate BDNF gene expression. Wu, X., Zhu, D., Jiang, X., Okagaki, P., Mearow, K., Zhu, G., McCall, S., Banaudha, K., Lipsky, R.H., Marini, A.M. J. Neurochem. (2004)
- Agonist- and subunit-dependent potentiation of glutamate receptors by a nootropic drug aniracetam. Tsuzuki, K., Takeuchi, T., Ozawa, S. Brain Res. Mol. Brain Res. (1992)
- Ionotropic glutamate receptor modulation preferentially affects NMDA receptor expression in rat hippocampus. Healy, D.J., Meador-Woodruff, J.H. Synapse (2000)
- Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus. Isaacson, J.S., Nicoll, R.A. Proc. Natl. Acad. Sci. U.S.A. (1991)
- Effects of aniracetam on extracellular levels of transmitter amino acids in the hippocampus of the conscious gerbils: an intracranial microdialysis study. Yu, S., Cai, J. Neurosci. Lett. (2003)